Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

Completed

• Conditions: Non Small Cell Lung Cancer

• Registration Number: NCT05205226
• Lead Sponsor: Hunan Province Tumor Hospital

Brief Summary

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-01
• Study Start: 2018-01-02
• Primary Completion: 2021-06-05
• Study Completion: 2022-01-02
• Study First Submitted: 2022-01-11
• Study First Submitted QC: 2022-01-11
• Last Update Submitted: 2022-01-11
• Study First Posted: 2022-01-25
• Last Update Posted: 2022-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 636

Inclusion Criteria

• ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy

Exclusion Criteria

• EGFR/ALK/ROS1 driver gene mutation
• Chemotherapy only
• Concurrent radio-chemotherapy
• Surgery
• Single-agent immunotherapy
• No treatment information available

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	January 2018 to June 2021	Progression free survival time

Secondary Outcome Measures

Name	Time	Method
RT	January 2018 to June 2021	radiotherapy control time

Trial Locations

Locations (1)

Hunan Cancer Hospital; 🇨🇳 Changsha, Hunan, China